← Back to Screener
Innoviva, Inc. Common Stock (INVA)
Price$23.60
Favorite Metrics
Price vs S&P 500 (26W)33.72%
Price vs S&P 500 (4W)3.45%
Market Capitalization$1.78B
P/E Ratio (Annual)6.55x
All Metrics
P/CF (Annual)9.02x
Book Value / Share (Quarterly)$15.71
P/TBV (Annual)1.60x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)7.48%
Cash Flow / Share (Quarterly)$2.50
Price vs S&P 500 (YTD)17.02%
Gross Margin (TTM)74.80%
Net Profit Margin (TTM)65.92%
EPS (TTM)$2.99
10-Day Avg Trading Volume0.60M
EPS Excl Extra (TTM)$2.99
Revenue Growth (5Y)4.08%
EPS (Annual)$3.20
ROI (Annual)18.96%
Gross Margin (Annual)74.80%
Net Profit Margin (5Y Avg)52.55%
Cash / Share (Quarterly)$7.59
P/E Basic Excl Extra (TTM)6.55x
Revenue Growth QoQ (YoY)24.84%
EPS Growth (5Y)10.12%
P/E Normalized (Annual)6.55x
ROA (Last FY)16.58%
Revenue Growth TTM (YoY)14.67%
EBITD / Share (TTM)$2.24
ROE (5Y Avg)31.01%
Operating Margin (TTM)39.81%
Cash Flow / Share (Annual)$2.50
P/B Ratio1.52x
P/B Ratio (Quarterly)1.27x
Net Income / Employee (Annual)$2
EV / Revenue (TTM)3.61x
Net Interest Coverage (TTM)1.30x
ROA (TTM)19.19%
EPS Growth QoQ (YoY)919.12%
EV / EBITDA (TTM)8.34x
EPS Incl Extra (Annual)$3.20
Current Ratio (Annual)14.64x
Quick Ratio (Quarterly)13.31x
3-Month Avg Trading Volume0.80M
52-Week Price Return33.04%
EV / Free Cash Flow (Annual)7.96x
P/E Incl Extra (TTM)6.55x
Revenue / Employee (TTM)$3
Tangible BV / Share (Quarterly)$12.52
P/S Ratio (Annual)4.32x
Asset Turnover (Annual)0.25x
52-Week High$25.14
Operating Margin (5Y Avg)71.09%
EPS Excl Extra (Annual)$3.20
Tangible BV CAGR (5Y)17.65%
26-Week Price Return37.71%
Quick Ratio (Annual)13.31x
13-Week Price Return23.05%
Total Debt / Equity (Annual)0.22x
Current Ratio (Quarterly)14.64x
Enterprise Value$1,483.817
Revenue / Share Growth (5Y)10.36%
Asset Turnover (TTM)0.29x
Book Value / Share Growth (5Y)24.17%
Revenue / Employee (Annual)$3
Inventory Turnover (Annual)2.84x
Pretax Margin (Annual)79.47%
Cash / Share (Annual)$7.59
3-Month Return Std Dev25.15%
Net Income / Employee (TTM)$2
EBITDA CAGR (5Y)-12.17%
EBITDA Interim CAGR (5Y)-13.77%
ROE (Last FY)23.12%
Net Interest Coverage (Annual)0.80x
EPS Basic Excl Extra (Annual)$3.20
P/FCF (TTM)9.53x
Receivables Turnover (TTM)4.58x
EV / Free Cash Flow (TTM)7.96x
Total Debt / Equity (Quarterly)0.22x
EPS Incl Extra (TTM)$2.99
Receivables Turnover (Annual)4.58x
ROI (TTM)21.88%
P/S Ratio (TTM)4.32x
Pretax Margin (5Y Avg)70.53%
Revenue / Share (Annual)$4.85
Tangible BV / Share (Annual)$12.52
Forward P/E12.49x
Free OCF CAGR (5Y)-9.85%
Price vs S&P 500 (52W)3.21%
P/E Ratio (TTM)6.55x
EPS Growth TTM (YoY)3397.08%
Year-to-Date Return19.66%
5-Day Price Return-1.16%
EPS Normalized (Annual)$3.20
ROA (5Y Avg)15.78%
Net Profit Margin (Annual)65.92%
Month-to-Date Return2.66%
Cash Flow / Share (TTM)$1.03
EBITD / Share (Annual)$2.06
EPS Growth (3Y)12.50%
Operating Margin (Annual)39.81%
LT Debt / Equity (Annual)0.22x
P/CF (TTM)9.02x
ROI (5Y Avg)17.85%
P/E Excl Extra (TTM)6.55x
LT Debt / Equity (Quarterly)0.22x
EPS Basic Excl Extra (TTM)$2.99
P/TBV (Quarterly)1.60x
P/B Ratio (Annual)1.27x
Inventory Turnover (TTM)2.84x
Pretax Margin (TTM)79.47%
Book Value / Share (Annual)$15.71
Price vs S&P 500 (13W)22.36%
Net Margin Growth (5Y)-0.21%
Beta0.44x
P/FCF (Annual)9.53x
Revenue / Share (TTM)$4.82
ROE (TTM)30.60%
52-Week Low$16.52
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.09
4.09
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
INVAInnoviva, Inc. Common Stock | 4.32x | 14.67% | 74.80% | 10.12% | $23.60 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Innoviva Inc generates revenue through a portfolio of pharmaceutical royalties and operating assets in critical care and infectious disease. Its holdings include branded respiratory therapies such as Trelegy, Anoro, and the Relvar/Breo/Ellipta franchise, which provide recurring revenue streams from established, marketed products.